ArticleMolecules (Basel, Switzerland)2023
3-Heptylidene-4,6-Dimethoxy-3
Silvia Cordeiro das Neves, Flavio Henrique de Araújo, Willian Ayala Correa, Allana Cristina Faustino Martins, Henrique Rodrigues Scherer Coelho, Marcelo Luiz Brandão Vilela, Valter Aragão do Nascimento, Candida Aparecida Leite Kassuya, Dênis Pires de Lima, Adilson Beatriz and 2 more
Open access · goldAbstract read
In one paragraphArticle in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors at 3 institutions in 2 countries.
Silvia Cordeiro das NevesStem Cell, Cell Therapy and Toxicological Genetics Research Centre (CeTroGen), Medical School, Federal University of Mato Grosso do Sul, Campo Grande 79080-190, MS, Brazil.ORCID 0000-0003-3276-4198 Flavio Henrique de AraújoStem Cell, Cell Therapy and Toxicological Genetics Research Centre (CeTroGen), Medical School, Federal University of Mato Grosso do Sul, Campo Grande 79080-190, MS, Brazil.
Willian Ayala CorreaInstitute of Chemistry, Federal University of Mato Grosso do Sul, Campo Grande 79070-900, MS, Brazil.
Allana Cristina Faustino MartinsDepartment of Pharmaceutical Sciences, North Dakota State University, Fargo, ND 58102, USA.ORCID 0000-0001-5647-2187 Henrique Rodrigues Scherer CoelhoStem Cell, Cell Therapy and Toxicological Genetics Research Centre (CeTroGen), Medical School, Federal University of Mato Grosso do Sul, Campo Grande 79080-190, MS, Brazil.ORCID 0000-0003-2438-6510 Marcelo Luiz Brandão VilelaMedical School, Federal University of Mato Grosso do Sul, Campo Grande 79070-900, MS, Brazil.
Valter Aragão do NascimentoGraduate Programme in Health and Development in the Midwest Region, Medical School, Federal University of Mato Grosso do Sul, Campo Grande 79070-900, MS, Brazil.
Candida Aparecida Leite KassuyaSchool of Health Sciences, Federal University of Grande Dourados, Dourados 79070-900, MS, Brazil.ORCID 0000-0002-8998-9219 Dênis Pires de LimaInstitute of Chemistry, Federal University of Mato Grosso do Sul, Campo Grande 79070-900, MS, Brazil.ORCID 0000-0002-6023-4867 Adilson BeatrizInstitute of Chemistry, Federal University of Mato Grosso do Sul, Campo Grande 79070-900, MS, Brazil.ORCID 0000-0001-6864-6092 Rodrigo Juliano OliveiraStem Cell, Cell Therapy and Toxicological Genetics Research Centre (CeTroGen), Medical School, Federal University of Mato Grosso do Sul, Campo Grande 79080-190, MS, Brazil.ORCID 0000-0003-3514-3346 Roberto da Silva GomesDepartment of Pharmaceutical Sciences, North Dakota State University, Fargo, ND 58102, USA.ORCID 0000-0002-8075-9716 Universidade Federal de Mato Grosso do Sul · BRNorth Dakota State University · USUniversidade Federal da Grande Dourados · BR
Funding
Targeting CLEC-2/podoplanin as a therapeutic strategy for pancreatic cancerP20GM109024 · NIGMS · NORTH DAKOTA STATE UNIVERSITY · PI Sanku Mallik · 2016 to 2026
$20.5MNIGMS NIH HHS P20 GM109024
6 · The paper itselfAbstract
3-heptylidene-4,6-dimethoxy-3
Indexed as
Anticarcinogenic AgentsAntineoplastic AgentsAnimalsApoptosisCisplatinCyclophosphamideDNA DamageMiceAnticarcinogenic AgentsAntineoplastic AgentsCisplatinCyclophosphamidechromosomal damagein vivoPhthalide 1toxicology
Identifiers
PMID36770711
PMCPMC9922015
OpenAlexW4317626537
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390